While Me-4FDG and other SGLT2-targeting PET tracers have shown promise, the development of more specific and sensitive SGLT2 tracers could enable more accurate diagnoses and personalized treatment strategies for conditions like diabetes and cancer. The gene discussed is SLC5A2; the disease is cancer.